Side effects ‐ hot flushes · women with symptomatic endometriosis
Gestrinone may leads to lower side effects: hot flushes compared with leuprolin (low certainty).
1 finding from 1 review
Prevalence of dyspareunia · women with symptomatic endometriosis
Mifepristone may leads to lower prevalence of dyspareunia compared with placebo (low certainty).
1 finding from 1 review
Side effects ‐ amenorrhoea · women with symptomatic endometriosis
Mifepristone leads to higher side effects: amenorrhoea compared with placebo (high certainty).
1 finding from 1 review
Side effects ‐ hot flushes · women with symptomatic endometriosis
Mifepristone leads to higher side effects: hot flushes compared with placebo (high certainty).
1 finding from 1 review
Pelvic pain · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes pelvic pain: none or mild compared with danazol (very low certainty).
1 finding from 1 review
Dysmenorrhoea: none or mild · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes dysmenorrhoea: none or mild compared with danazol (very low certainty).
1 finding from 1 review
Dyspareunia: none or mild · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes dyspareunia: none or mild compared with danazol (very low certainty).
1 finding from 1 review
Side effects ‐ hirsutism · women with symptomatic endometriosis
It is very uncertain whether gestrinone changes side effects: hirsutism compared with danazol (very low certainty).
1 finding from 1 review
Decreased breast size · women with symptomatic endometriosis
Gestrinone may leads to lower decreased breast size compared with danazol (low certainty).
1 finding from 1 review
Global State: clinically important improvement · patients with schizophrenia
It is very uncertain whether chlorpromazine changes global state: clinically important improvement Clinical Global… compared with metiapine (very low certainty).
2 findings from 1 review
Adverse effects. Specific: movement disorders ‐ parkinsonism · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects. Specific: movement disorders ‐ parkinsonism compared with metiapine (very low certainty).
1 finding from 1 review
Service use: readmission due to relapse · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfaction of participant or care provider with treatment · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: aggressive or violent behaviour · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes: Cost of care · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · peripheral nerve block
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · peripheral nerve block
3 findings from 1 review
no estimate extracted
3 studies · 217 participants
Low
no estimate extracted
5 studies · 309 participants
Moderate
no estimate extracted
3 studies · 227 participants
Low
All‐cause mortality maximum · patients with acute coronary syndrome
Drug‐eluting stents showed no clear difference in all‐cause mortality at maximum compared with bare‐metal stents (low certainty).
1 finding from 1 review
Serious adverse events maximum · patients with acute coronary syndrome
Drug‐eluting stents may leads to lower serious adverse events at maximum compared with bare‐metal stents (low certainty).
1 finding from 1 review